Exercise or conversion by Sanjay Shukla of 10375 shares of ATyr Pharma subject to Rule 16b-3

About 67% of ATyr Pharma's investor base is looking to short. The analysis of current outlook of investing in ATyr Pharma suggests that many traders are alarmed regarding ATyr Pharma's prospects. The current market sentiment, together with ATyr Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use ATyr Pharma stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Atyr Pharma Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Read at macroaxis.com
ATyr insider trading alert for exercise of common stock by Sanjay Shukla, President and CEO, on 6th of February 2024. This event was filed by Atyr Pharma Inc with SEC on 2024-02-06. Statement of changes in beneficial ownership - SEC Form 4

ATyr Pharma Fundamental Analysis

We analyze ATyr Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ATyr Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ATyr Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Debt

Total Debt Comparative Analysis

ATyr Pharma is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

ATyr Pharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ATyr Pharma stock to make a market-neutral strategy. Peer analysis of ATyr Pharma could also be used in its relative valuation, which is a method of valuing ATyr Pharma by comparing valuation metrics with similar companies.

Peers

ATyr Pharma Related Equities

XFORX4 Pharmaceuticals   13.85   
0%
100.0%
AMLXAmylyx Pharmaceuticals   2.39   
0%
17.0%
PDSBPDS Biotechnology   1.03   
0%
7.0%
DAWNDay One   0.16   
0%
1.0%
MREOMereo BioPharma   1.45   
10.0%
0%
HOOKHookipa Pharma   1.84   
13.0%
0%
TERNTerns Pharmaceuticals   2.58   
18.0%
0%
INZYInozyme Pharma   2.65   
19.0%
0%
ABOSAcumen Pharmaceuticals   8.67   
62.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in ATyr Stock

If you are still planning to invest in ATyr Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ATyr Pharma's history and understand the potential risks before investing.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum